CTRI/2017/09/009693
Active, not recruiting
Phase 3
The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TBVersion 6.2 dated feb 2015 - STREAM
The international Union Against Tuberculosis and lung diseases0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The international Union Against Tuberculosis and lung diseases
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A patient will be eligible for randomisation into the study (Stage 2\) if he/she:
- •1\.Is willing and able to give informed consent to participate in the trial treatment and follow\-up (signed or witnessed consent if the patient is illiterate)
- •2\.Is aged 18 years or older
- •3\.Has a positive AFB sputum smear result at screening (at least scanty), unless they are HIV positive in which case a positive GeneXpert result within four weeks prior to screening is sufficient
- •4\.Has evidence of resistance to rifampicin either by line probe assay (Hain Genotype21\), GeneXpert or culture\-based drug susceptibility testing (DST), from a test performed at screening or from a test performed within the four weeks prior to screening
- •5\.Is willing to have an HIV test and, if positive, is willing to be treated with ART in accordance with the national policies but excluding ART contraindicated for use with bedaquiline
- •6\.Is willing to use effective contraception: pre\-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilised must agree to use a barrier method or an intrauterine device unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms. In Stage 2 pre\-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilised must agree to use two methods of contraception, for example a hormonal method and a barrier method.
- •7\.Resides in the area and expected to remain for the duration of the study.
- •8\.Has had a chest X\-ray at that is compatible with a diagnosis of pulmonary TB (if such a chest X\-ray taken within 4 weeks of randomisation is available, a repeat X\-ray is not required)
- •9\.Has normal K\+, Mg2\+ and corrected Ca2\+ at screening.
Exclusion Criteria
- •A patient will not be eligible for randomisation into the study ( Stage 2\) if he/she:
- •1\.Is infected with a strain of M. tuberculosis resistant to a second\-line injectables by line probe assay (Hain Genotype21\)
- •2\.Is infected with a strain of M. tuberculosis resistant to a fluoroquinolone by line probe assay (Hain Genotype21\)
- •3\.Has tuberculous meningitis or bone and joint tuberculosis
- •4\.Is critically ill, and in the judgment of the investigator, unlikely to survive more than 4 months
- •5\.Is known to be pregnant or breast\-feeding
- •6\.Is unable or unwilling to comply with the treatment, assessment, or follow\-up schedule
- •7\.Is unable to take oral medication
- •8\.Has AST or ALT more than 5 times the upper limit of normal for Stage 1, and AST or ALT more than 3 times the upper limit of normal for Stage 2
- •9\.Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of a treatment regimen for acromegalyEUCTR2010-023674-39-ATÖsterreichisches Akromegalie Register
Not yet recruiting
Not Applicable
Mangement of Bleeding from gums through Ayurvedic treatment protocolHealth Condition 1: null- Patients Suffering from Shonitanugami ShitadCTRI/2018/06/014536Govt Akhandanand ayurved College
Completed
Not Applicable
Evaluation of the treatment standard: Treatment of severe acute lung injury by extracorporeal membrane oxygenatiosevere acute respiratory distress syndromeDRKS00013967niversitätsmedizin Mannheim24
Recruiting
Not Applicable
Comparison of the effect of TDCS and RTMS in the treatment of migraineIRCT20190404043159N4Esfahan University of Medical Sciences72
Not yet recruiting
Not Applicable
Study on parameters and efficacy of treatment with denosumab for bone metastases of prostate cancerJPRN-UMIN000009985Gifu University30